文献速递肾移植

瑞德西韦对COVID-19感染移植受者他克莫司暴露的潜在影响

Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection.
PubMed 文献 · Kidney Int Rep · 2023-04-30

这项回顾性研究纳入61例因COVID-19住院并接受瑞德西韦的成人实体器官移植受者(56例用他克莫司,5例用环孢素),评估瑞德西韦对钙调神经磷酸酶抑制剂(CNI)水平的影响。开始瑞德西韦后他克莫司水平中位升高84.8%,仅3例CNI水平无显著变化;他克莫司谷浓度最大升幅中位时间为3天,瑞德西韦疗程结束后需10天恢复基线。作者认为瑞德西韦启动后CNI水平显著升高,但需未来研究进一步评估该相互作用。

要点

  • 开始瑞德西韦后他克莫司水平中位升高84.8%,仅3例CNI水平无显著变化。
  • 他克莫司谷浓度最大升幅中位时间3天,瑞德西韦疗程结束后10天恢复基线。
  • 他克莫司中位升幅在肺和肾移植受者中比他克莫司心脏移植受者更明显(96.5% vs 93.9% vs 64.6%)。

核心结论

  • 这项回顾性分析表明,开始瑞德西韦后CNI水平显著升高,但需未来研究进一步评估该相互作用。

研究设计与样本

  • 回顾性研究,纳入因COVID-19住院并接受瑞德西韦的成人实体器官移植受者,且正在使用CNI。
  • 排除开始使用其他已知与CNI相互作用药物的患者。
  • 筛查86例,纳入61例(56例使用他克莫司,5例使用环孢素)。
  • 大多数患者接受肾移植(44.3%),各移植器官间基线人口学特征相似。

主要发现

  • 开始瑞德西韦后他克莫司水平中位升高84.8%,仅3例患者CNI水平无显著变化。
  • 他克莫司中位升幅在肺和肾移植受者中比他克莫司心脏移植受者更明显(96.5% vs 93.9% vs 64.6%)。
  • 他克莫司谷浓度最大升幅的中位时间为3天。
  • 瑞德西韦疗程结束后需10天他克莫司水平恢复基线。

关键数值与推荐

  • 主要终点为开始瑞德西韦后CNI水平的变化百分比。
  • 次要终点包括CNI谷浓度达到最大升幅的时间、急性肾损伤(AKI)发生率及CNI水平恢复正常的时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。
  • 作者指出需未来研究进一步评估该相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Remdesivir has proven to have benefits against COVID-19 infection. However, data supporting drug-drug interactions are insufficient. Clinicians have noticed that calcineurin inhibitor (CNI) levels tend to change after starting remdesivir. This retrospective study aimed to evaluate the effect of remdesivir on CNI levels. METHODS: This study included adult solid organ transplant recipients hospitalized for COVID-19 who received remdesivir while on CNI. Patients were excluded if they started on other medications known to interact with CNI. The primary end point was the percentage of change in CNI levels after starting remdesivir. Secondary end points included the time until CNI levels reached a maximum increase in trough levels, the incidence of acute kidney injury (AKI), and the time until CNI levels normalized. RESULTS: Of the 86 patients screened, 61 were included (56 on tacrolimus and 5 on cyclosporine). Most patients received kidney transplants (44.3%), and baseline demographics were similar among the transplanted organs. The median increase in tacrolimus level after starting remdesivir was 84.8%, and only 3 patients had no significant change in CNI levels. The median increase in tacrolimus level was more pronounced in lung and kidney recipients than in heart recipients (96.5% vs. 93.9% vs. 64.6 %, respectively). The median time to maximum increase in tacrolimus trough levels was 3 days, and it took 10 days after the remdesivir course for levels to return to baseline. CONCLUSION: This retrospective analysis demonstrates that CNI levels were significantly elevated after starting remdesivir. However, future studies are warranted to evaluate this interaction further.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Habeeb E, Gabardi S, Townsend K, et al. Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection. Kidney Int Rep. 2023. PMID: 37360819. doi:10.1016/j.ekir.2023.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。